Skip to content
Loading…
Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis’s $12 billion takeover of Avidity Biosciences and raises questions about the drugmaker’s growth prospects.…
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.